Hikal Limited — Investor Meet, 10-02-2025: Analysts/Institutional Investor Meet/Con. Call Updates

1. Financial Performance: Hikal Ltd. reported revenue of INR 448 crores for Q3 FY25, showing an 11% year-over-year increase in EBITDA to INR 72 crores. For the nine-month period, revenue reached INR 1,307 crores, reflecting a growth of 3%, while EBITDA grew by 18% to INR 205 crores. Operating cash flow also improved, amounting to INR 102 crores year-over-year.

2. Future Outlook and Growth Drivers: Management highlighted a stabilizing global chemical market and anticipates ongoing growth backed by new facility ramp-ups, increased operational efficiencies, and a focus on sustainable practices. Expanding their API business and entering new geographies are crucial elements of their growth strategy.

3. Order Book and Operational Updates: Hikal is set to benefit from a growing order book within the CDMO segment, as several products are moving towards validation and commercialization. The newly capitalized multipurpose facility in Panoli is expected to boost future production capacities.

4. Analyst Q&A Insights (Detailed):

- Revenue and Profitability: Analysts sought clarity on revenue projections and margin expectations, which management sees improving as new products are commercialized.

- Market Position and Competitive Landscape: Questions about competition, particularly from China, were discussed, with management emphasizing a strategic shift towards NCEs and innovative products.

- Operational Challenges or Risks: Concerns over pricing pressures were acknowledged, but the management expressed confidence in mitigating risks and adapting to market challenges.

- Capex and Capital Allocation: Plans include consistent annual capex of INR 150-200 crores, predominantly for growth initiatives and replacement capex.

- Strategic Priorities and Long-Term Vision: Discussions focused on maintaining a robust pipeline for both the Pharma and Crop Protection divisions and enhancing margins through targeted business strategies.

5. Market or Regulatory Updates: The call addressed evolving market dynamics benefiting from shifts away from China for sourcing chemicals, aligning with new global economic trends.

6. Strategic Focus Areas: There is a substantial focus on innovation, sustainability, and enhancing operational efficiency, indicating management's forward-looking approach to market competition.

7. Investor Insight: Hikal's solid financial performance and growth projections suggest a positive outlook, warranting consideration for a 'buy' position as they navigate challenges and leverage opportunities for long-term growth.